293 results about "Therapy eye" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

An ophthalmic lens configured to correct and / or treat at least one condition of the eye (e.g., presbyopia, myopia, hyperopia, astigmatism, binocular vision disorders, night vision image quality, and / or visual fatigue syndrome) comprising: a base power profile; and at least one pulse selected to modify the base power profile.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

An ophthalmological device and system is described that allows the simultaneous imaging of an eye using both scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT). Further the device and system is capable of targeting and delivering a treatment laser for treatment of an eye condition.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention relates to a photoreceptor cell specific bidirectional promoter and application thereof. Specifically, the invention relates to a novel photoreceptor cell specific bidirectional promoter, an expression cassette containing the bidirectional promoter, a vector, a viral particle, a cell and a pharmaceutical composition, and application of the bidirectional promoter to treatment of eye diseases, such as retinal diseases.

The invention provides methods of treating an eye disorder and compositions for use therein, the methods comprising applying a crosslinkable liquid composition onto an anterior corneal surface of said eye using a mold; crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a crosslinked composition on the anterior corneal surface of the eye; and correcting the curvature of the crosslinked composition.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral, amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

A system for treating a media opacity in a vitreous media of an eye includes a visualization module adapted to provide visualization data of a portion of the eye via one or more viewing beams. The system includes a laser module adapted to selectively generate a treatment beam directed towards the media opacity in order to disrupt the media opacity. The laser module and the visualization module have a shared aperture for guiding the treatment beam and the one or more viewing beams towards the eye, the shared aperture being centered about a central axis. A controller is configured to acquire one or more defining parameters of the media opacity and determine when the media opacity is with a predefined target zone of a real-time viewing window. The media opacity is treated with the treatment beam when the media opacity is within the predefined target zone.

A light based system for treating an eye includes a mask that is configured for positioning on the eye and a light source that is configured to deliver therapeutic light. The mask has an inner surface that is positionable against the eye and an outer surface that is opposite the inner surface. The mask is optically opaque to prevent transmission of light through the mask and the mask includes at least one transparent opening that allows transmission of light through the mask to target tissue of the eye posterior the transparent opening. The light source is positioned relative to the mask so that the delivered therapeutic light irradiates at least a portion of the mask and the transparent opening. Therapeutic light traverses through the transparent opening to the target tissue positioned posterior the transparent opening.

Systems, devices and methods are provided that provide assistance in selecting appropriate interventions for treatment of disease and injury to the eye. Systems of the inventive concept provide cloud-based processing and storage of clinical and patient-specific data, which can provide treatment recommendations and projected outcomes to a practitioner using a local device. Systems, devices, and methods can generate interactive physiomechanical models of the eye of a specified individual, which are derived measurements of mechanical properties of structures of the eye. The physiomechanical model is interactive, and can be used to emulate the effects of one or more medical interventions in the eye in order to implement an optimized treatment plan for the individual.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

Disclosed herein are methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.

Provided herein are methods and compositions for improving the visual function of an eye having an ocular disorder. Provided herein are methods of treating an ocular lesion of an eye of an individual, the method comprising: (a) administering a first composition comprising a Fas inhibitor. In some embodiments, the method further comprises (b) administering a second composition comprising a Fas inhibitor, where the second composition is administered for about 10 weeks or more after the first composition is administered.